Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
European Urology Oncology|March 14, 2024
A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate CancerEmmy Boerrigter, Joanneke K Overbeek, Guillemette E Benoist, et al.
BJU International|February 18, 2009
Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomyJoep G H van Roermund, Dieuwertje E G Kok, Mark F Wildhagen, et al.
BJU International|May 8, 2014
Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based surveyCristian I Surcel, Prasanna Sooriakumaran, Alberto Briganti, et al.
Frontiers in Oncology|December 13, 2021
Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort StudyMarie-Christina Jahreiß, Wilma D Heemsbergen, Bo van Santvoort, et al.
Urologic Oncology|December 23, 2020
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapyMaarten J van der Doelen, Niven Mehra, Inge M van Oort, et al.
Prostate Cancer and Prostatic Diseases|October 1, 2020
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathologyBastiaan M Privé, Bas Israël, Melline G M Schilham, et al.
Clinical Chemistry|May 15, 2020
Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational StudyGuillemette E Benoist, Inge M van Oort, Emmy Boerrigter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2023
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate CancerSofie H Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi, et al.
The Oncologist|September 20, 2022
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety AnalysesNiven Mehra, Karim Fizazi, Johann S de Bono, et al.
Cancers|August 26, 2022
Psychosocial Aspects of Living Long Term with Advanced Cancer and Ongoing Systemic Treatment: A Scoping ReviewEvie E M Kolsteren, Esther Deuning-Smit, Alanna K Chu, et al.
Pageof 14